1. Home
  2. RAND vs LGVN Comparison

RAND vs LGVN Comparison

Compare RAND & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rand Capital Corporation

RAND

Rand Capital Corporation

HOLD

Current Price

$10.90

Market Cap

34.6M

Sector

Finance

ML Signal

HOLD

Logo Longeveron Inc.

LGVN

Longeveron Inc.

HOLD

Current Price

$1.07

Market Cap

34.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RAND
LGVN
Founded
1969
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.6M
34.0M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
RAND
LGVN
Price
$10.90
$1.07
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
3.5K
1.2M
Earning Date
05-04-2026
05-07-2026
Dividend Yield
10.87%
N/A
EPS Growth
N/A
50.76
EPS
N/A
N/A
Revenue
N/A
$709,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$10.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.05
$0.48
52 Week High
$21.30
$1.83

Technical Indicators

Market Signals
Indicator
RAND
LGVN
Relative Strength Index (RSI) 40.69 57.76
Support Level $10.53 $0.69
Resistance Level $11.15 $1.23
Average True Range (ATR) 0.31 0.10
MACD -0.10 -0.01
Stochastic Oscillator 19.46 59.04

Price Performance

Historical Comparison
RAND
LGVN

About RAND Rand Capital Corporation

Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. Its investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.

About LGVN Longeveron Inc.

Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.

Share on Social Networks: